Compare Novavax Inc (NVAX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Williams-Sonoma, Inc. — how do they compare? Novavax Inc trades at $12.83 (market cap $1.82B), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 15.5× Novavax Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Williams-Sonoma, Inc. for 59 Days on average.
| NVAX | WSM | |
|---|---|---|
Market Cap | $1.82B | $28.15B |
Volume | 6,198,505 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.56 | $251.81 |
52-Week Low | $6.22 | $168.64 |
Typical Hold Time | 59 Days | 59 Days |
Enterprise Value | $1.39B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Williams-Sonoma (WSM) trades at $241.75, up 0.54% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing the $2.08 expectation. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high ROE of 54.96%. Recent news highlights market share gains and profitability improvements, including a new Pottery Barn collaboration and store expansion.
The outlook for WSM is positive, driven by earnings momentum, margin strength, and strategic initiatives. However, risks include competitive pressures in home furnishings and sensitivity to housing market trends. Analyst consensus is a buy with a $246.31 price target, suggesting modest upside from current levels, supported by institutional confidence and dividend declarations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
